Short Description

Detection of minimal residual disease in Acute Lymphoblastic Leukemia predicts outcome. This assay helps to identify patients at higher/lower risk of relapse. Detection of minimal residual disease is important for risk assessment and stratification of therapy. It detects sub microscopic levels of leukemia with a_x000D_ clinical sensitivity of 0.01%.

PreTest Information

It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history.

Detail Description

MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS FOR T-ALL

T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects the lymphoid cells. It is a rare form of leukemia, accounting for about 15% of all cases of acute lymphoblastic leukemia (ALL). While T-ALL can affect people of all ages, it is more common in children and teenagers.

Minimal residual disease (MRD) analysis is a test used to detect very small amounts of cancer cells that may be present in the body after treatment. This test is important in monitoring the effectiveness of treatment for T-ALL.

Symptoms of T-ALL

The symptoms of T-ALL are similar to those of other types of leukemia. They may include:

• Fever
• Weakness or fatigue
• Weight loss
• Bone pain
• Easy bruising or bleeding
• Swollen lymph nodes
• Enlarged spleen or liver
• Shortness of breath
• Frequent infections

Diagnosis of T-ALL

Diagnosis of T-ALL involves a series of tests, including:

• Physical exam and medical history
• Blood tests
• Bone marrow biopsy
• Lumbar puncture (spinal tap)
• Imaging tests (such as X-rays, CT scans, or MRI scans)

MRD Analysis for T-ALL

MRD analysis is a highly sensitive test that can detect very small amounts of cancer cells in the body. This test is used to monitor the effectiveness of treatment for T-ALL.

During MRD analysis, a sample of bone marrow or blood is taken from the patient. This sample is then analyzed in a laboratory to detect any cancer cells that may be present.

The results of MRD analysis can help doctors determine if further treatment is necessary or if the patient is in remission.

Test Cost

The cost of MRD analysis for T-ALL in India is approximately INR 18000.

Conclusion

MRD analysis is an important tool in the treatment and monitoring of T-ALL. If you or a loved one is experiencing symptoms of T-ALL, it is important to seek medical attention right away. Early diagnosis and treatment can improve the chances of a successful outcome.

At DNA Labs India, we offer MRD analysis for T-ALL at an affordable cost. Contact us today to learn more about this test and how it can help in the treatment of T-ALL.

Detection of minimal residual disease in Acute Lymphoblastic Leukemia predicts outcome. This assay helps to identify patients at higher/lower risk of relapse. Detection of minimal residual disease is important for risk assessment and stratification of therapy. It detects sub microscopic levels of leukemia with a clinical sensitivity of 0.01%.